Despite weight loss, most obesity medications do not significantly improve quality of life, according to a study

I find the article to be well-researched, timely, and of high quality. Its main value lies in the fact that it doesn’t merely measure weight loss in kilograms, but rather analyzes aspects that are more relevant to the patient: quality of life, cardiovascular health, adverse effects, treatment discontinuation, and loss of lean body mass. In a field that generates a lot of media hype, it helps set expectations straight.

The study aligns with what we already knew: some medications lead to significant weight loss, but losing weight does not automatically mean improving all aspects of health. The scale tells part of the story, but not the whole story.

The fact that the cardiovascular profile improves only slightly can be explained by the fact that cardiovascular risk depends on many factors besides weight: blood pressure, blood glucose, lipids, inflammation, age, pre-existing conditions, diet, physical activity, and muscle mass. Furthermore, one year may be too short a time to detect clear benefits regarding cardiovascular events.

The practical implication is that these drugs should be evaluated based on more than just the kilograms lost: one must consider overall health, tolerability, cost, adherence, muscle preservation, and long-term benefits.

[Regarding potential limitations] Many trials have a relatively short follow-up period; there are few direct comparisons between drugs; and trial participants do not always represent real-world patients. Caution is also warranted with newer drugs, as some results are promising but the evidence is still limited.

In summary, these drugs are an important tool, but not a magic solution. In obesity, success should not be measured solely in kilograms, but in health, function, and quality of life.

This is a comprehensive and methodologically sound review, involving nearly 100,000 participants, and it has the merit of evaluating these treatments not only based on weight loss but also on their effects on quality of life, cardiovascular events, muscle mass, and adverse effects. Its main conclusion is reasonable: losing more weight does not automatically mean a better quality of life or an immediate reduction in cardiovascular risk.

However, the results must be interpreted with caution. Most of the trials were relatively short and were not designed to detect heart attacks, mortality, or kidney disease. These benefits require years of follow-up and are primarily seen in patients who already have a high cardiovascular risk. Therefore, the study does not prove that these drugs lack cardiovascular benefits, but rather that for many of them, we do not yet have sufficient evidence. Furthermore, cardiovascular risk depends not only on weight loss but also on age, pre-existing conditions, improvements in glucose levels, blood pressure, and lipid profiles, and possibly on the specific effects of each medication.

The absence of a large average improvement in quality of life may also be explained by the fact that very different scales were combined and that adverse effects, fatigue, or loss of muscle mass may offset part of the perceived benefit. Comparisons between medications are, moreover, mostly indirect, and no individual data are available to determine which patients benefit the most. This is a very useful study for guiding shared decision-making, but it does not yet allow us to identify an absolute winner or rule out long-term benefits.

[Regarding the editorial accompanying the study in the same journal]

The editorial provides an appropriate context for the study and is correct in emphasizing that treatment must be individualized, taking into account not only weight loss but also comorbidities, adverse effects, adherence, cost, and patient preferences. However, it is an editorial opinion piece, not new research, and it is somewhat optimistic regarding the possibility of choosing the ideal medication: the meta-analysis itself lacks individual-level data, and a significant portion of the comparisons is based on indirect evidence. Its strongest message is that not all patients need the same treatment and that long-term studies with clinically relevant outcomes are still lacking.